EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From Demyelination to Intervention: Natural Compounds as Emerging Therapeutic Targets in Multiple Sclerosis Neuroinflammation

Zhiyong Long iD, Qianyue Yang iD, Yonghe Wu iD, Lifei Wan iD, Liuting Zeng iD, Lingyun Sun iD

Journal of Immunology Research · 2026-01 · 2026 (1)

DOI: 10.1155/jimr/6333512 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Immunology Research, online erschienen am 26.03.2026. Verfasst von Zhiyong Long und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Medicine and Rehabilitation, The Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Multiple Sclerosis, Biological Products, Demyelinating Diseases, Neuroinflammatory Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 230 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a chronic immune‐mediated inflammatory demyelinating disease of the central nervous system (CNS), characterized by multifocal lesions, axonal damage, and progressive neurological dysfunction, imposing a heavy burden on patients and healthcare systems. While T lymphocytes have long been regarded as central to MS pathogenesis, accumulating evidence underscores the pivotal role of B lymphocytes and dysregulated cytokine networks (e.g., Th17/IL‐17 and NF‐κB pathways) in driving disease initiation and progression. Despite advances in symptomatic management and disease‐modifying therapies (DMTs), clinical interventions for MS remain constrained by severe side effects, drug dependency, and suboptimal long‐term efficacy, highlighting an urgent unmet need for novel therapeutic strategies. Natural compounds (e.g., alkaloids, flavonoids, terpenoids, and polyphenols) have emerged as promising candidates owing to their inherent biocompatibility, favorable safety profiles, and multi‐targeted regulatory effects on neuroinflammation. This review critically synthesizes and evaluates current evidence on the therapeutic potential of natural compounds in MS, with a focus on cross‐compound class integration of core common pathways (e.g., NF‐κB inhibition and Th17/Treg balance modulation) rather than isolated mechanism descriptions. We explicitly compare the strength of evidence across different natural compounds, clarifying which findings are well‐substantiated versus preliminary. Notably, we emphasize the inherent limitations of experimental autoimmune encephalomyelitis (EAE) models in recapitulating human MS pathophysiology (e.g., interspecies immune divergence and disease heterogeneity) and integrate or at least reference relevant clinical/epidemiological evidence to enhance translational relevance. Finally, we outline key future perspectives, including the integration of natural products with existing DMTs, challenges in clinical trial design, and prospects of combination therapies, aiming to provide a directional framework for advancing natural compounds from preclinical exploration to actionable clinical therapeutic targets in MS and enhancing the translational impact of this field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisBiological ProductsDemyelinating DiseasesNeuroinflammatory DiseasesHumansAnimalsTh17 CellsMolecular Targeted Therapy

Stichwörter der Autor:innen

demyelinationexperimental autoimmune encephalomyelitismultiple sclerosisnatural compoundsneuroinflammationtherapeutic targettranslational research

Substanzen

Biological Products

Autor:innen und Institutionen

  • Department of Physical Medicine and Rehabilitation, The Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, China.
  • Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China, njmu.edu.cn.
  • Department of Rheumatology, The First People's Hospital of Changde City, Changde, China, yy.changde.gov.cn/.
  • Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China, pumc.edu.cn.

ORCID-Profile: Zhiyong Long, Qianyue Yang, Yonghe Wu, Lifei Wan, Liuting Zeng, Lingyun Sun

Zitieren

APA

Long, Z., Yang, Q., Wu, Y., Wan, L., Zeng, L., & Sun, L. (2026). From Demyelination to Intervention: Natural Compounds as Emerging Therapeutic Targets in Multiple Sclerosis Neuroinflammation. Journal of Immunology Research, 2026(1). https://doi.org/10.1155/jimr/6333512

Vancouver

Long Z, Yang Q, Wu Y, Wan L, Zeng L, Sun L. From Demyelination to Intervention: Natural Compounds as Emerging Therapeutic Targets in Multiple Sclerosis Neuroinflammation. Journal of Immunology Research. 2026;2026(1). doi:10.1155/jimr/6333512

BibTeX
@article{Long2026,
  author = {Long, Zhiyong and Yang, Qianyue and Wu, Yonghe and Wan, Lifei and Zeng, Liuting and Sun, Lingyun},
  title = {From Demyelination to Intervention: Natural Compounds as Emerging Therapeutic Targets in Multiple Sclerosis Neuroinflammation},
  journal = {Journal of Immunology Research},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/jimr/6333512}
}
Kostenlos starten →